Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
NCT06050252Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Jul 2024
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in intrahepatic cholangiocarcinoma (ICC), sponsored by National Cancer Institute. Started Jul 2024; status: suspended.
02
Drugs
durvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06050252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050252.